Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years
Eagle Pharmaceuticals (OTCMKTS: EGRX) has announced the availability of proxy materials for its upcoming 2025 Annual Meeting of Stockholders, scheduled for October 17, 2025 at 10:00 a.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eagle Pharmaceuticals (OTCMKTS: EGRX) has announced the availability of proxy materials for its upcoming 2025 Annual Meeting of Stockholders, scheduled for October 17, 2025 at 10:00 a.m. Eastern Time. The meeting will be held virtually.
Stockholders of record as of August 18, 2025 will receive a Notice of Internet Availability of Proxy Materials. All proxy materials, including the notice, proxy information statement, and proxy card, along with the company's audited financial statements for 2023 and 2024, can be accessed through www.proxyvote.com and the company's investor relations website.
Details
News Market Reaction – EGRX
On Sep 18, the first trading day after this news, EGRX closed 17.85% below the previous close.
Data tracked by StockTitan Argus for the Sep 18 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WOODCLIFF LAKE, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders, which is scheduled to be held virtually on October 17, 2025 at 10:00 a.m. Eastern Time.
The Company is delivering a Notice of Internet Availability of Proxy Materials (“Notice”) to stockholders of record as of the close of business on August 18, 2025. The proxy materials relating to the 2025 Annual Meeting of Stockholders, including the Notice, proxy information statement and proxy card, are available at www.proxyvote.com and https://investor.eagleus.com/events-presentations. In addition, the Company’s audited financial statements as of and for the years ended December 31, 2024 and 2023, are available at https://investor.eagleus.com/events-presentations.
About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. Additional information is available on Eagle’s website at www.eagleus.com.
Investor Relations Contact
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.